The MDSC (CD11b+Gr1+) were the predominant CD11b+ population in the isotype-treated tumor bearing mice but were reduced in all three immunotherapy treatment groups of anti-PD-1, anti CX3CR1, and anti-PD-1 + anti CX3CR1 (Figure 4B). Here, ITGAM is linked to neoplasm.